Catalyst

Slingshot members are tracking this event:

Phase 2 data of INOpulse delivery device for Pulmonary Hypertension associated with COPD and Idiopathic Pulmonary Fibrosis expected Q1 2017

Source Link:
http://investors.bellerophon.com/phoenix.zhtml?c=253899&p=irol-newsArticle&ID=2111739

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
BLPH Community voting in process
SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details "We also plan to continue Phase 2 testing with patients suffering Pulmonary Hypertension associated with COPD (PH-COPD) and to commence clinical testing with patients suffering Pulmonary Hypertension associated with Idiopathic Pulmonary Fibrosis (PH-IPF). We should have results from these tests by the end of 2016.”
http://investors.bel...
Additional Relevant Details Update on November 8 2016: Our Phase 2 trials for INOpulse therapy to treat pulmonary hypertension (PH) associated with chronic obstructive pulmonary disease (PH-COPD) and idiopathic pulmonary fibrosis (PH-IPF) have been initiated and are actively recruiting. We look forward to communicating results of each during the first quarter of 2017.
http://investors.bel...
Additional Relevant Details Clinicaltrials.gov page lists March 2018 as expected completion date.
https://clinicaltria...
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
May 01, 2017
Occurred Source:
http://investors.bellerophon.com/phoenix.zhtml?c=253899&p=irol-newsArticle&ID=2268250
Related Projects Image
Related Keywords Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension Associated With Copd, Ph-copd, Inopulse, Pah Therapies
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.